Bayer’s Pediatric Study on Rivaroxaban: A Potential Game-Changer for VTE Treatment

Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.

Study Overview: Bayer AG, in collaboration with Janssen Research & Development, LLC, is conducting an observational study titled Xarelto Paediatric VTE PASS Drug Utilization Study. This study aims to evaluate the usage patterns and safety of Rivaroxaban oral suspension in children under two years old diagnosed with venous thromboembolism (VTE). The study’s significance lies in its focus on a vulnerable pediatric population, where limited data currently exists regarding the drug’s safety and efficacy.

Intervention/Treatment: The study investigates the use of Rivaroxaban (Xarelto, BAY59-7939), an anticoagulant, alongside standard care treatments for VTE, such as heparins and Vitamin K antagonists. The goal is to understand how these treatments are used and their safety profiles in young children.

Study Design: This is a retrospective, observational cohort study. It will collect data from electronic health records and health insurance claims across several European countries. The primary purpose is to observe and document the real-world application and safety of VTE treatments in children under two.

Study Timeline: The study is set to begin on December 31, 2025, with data collection continuing until 2026. The last update was submitted on August 19, 2025, indicating the study is still in the planning stages and has not yet begun recruiting participants.

Market Implications: The study’s findings could significantly impact Bayer’s stock performance by providing insights into the pediatric application of Rivaroxaban, potentially expanding its market. As the study progresses, investor sentiment may be influenced by the safety and efficacy data, especially in comparison to competitors offering alternative VTE treatments.

The study is ongoing, with further details available on the ClinicalTrials portal.